Joshua James
Overview
Energetic and committed, Joshua James helps clients strengthen and enforce their intellectual property rights. Josh’s practice focuses on patent litigation, particularly Hatch-Waxman pharmaceutical litigation in federal courts and inter partes review proceedings before the Patent Trial and Appeal Board.
Career & Education
- Illinois Institute of Technology (IIT)
Research Experience for Undergraduates, June 2010–August 2011
Inter-Professional Research Opportunity (IPRO), January 2011–May 2011
Biomedical Engineering Senior Design, August 2009–May 2010
Research Experience for Undergraduates, June 2009–August 2009 - Rehabilitation Institute of Chicago
Research Experience for Undergraduates, June 2008–August 2008
- Illinois Institute of Technology (IIT)
- Illinois Institute of Technology, B.S., Summa cum Laude, chemical engineering, 2011
- Illinois Institute of Technology, B.S., Summa cum Laude, biomedical engineering, 2011
- Indiana University - Bloomington, Maurer School of Law, J.D., cum Laude, 2014
- Illinois
- U.S. Patent and Trademark Office (USPTO)
- U.S. District Court for the Northern District of Illinois
- U.S. Court of Appeals for the Federal Circuit
- Supreme Court of the United States
Professional Activities and Memberships
- PTAB Bar Association, 2016–present
- American Intellectual Property Law Association, 2011–present
- Chicago Bar Association, 2015–present
- Indiana Law Journal, Board Member, 2013–2014
- Intellectual Property Association, 2011–2014
- Phi Alpha Delta, Clerk, 2013
Joshua 's Insights
Client Alert | 3 min read | 05.26.26
On May 13, 2026, the U.S. Court of Appeals for the Federal Circuit affirmed a district court judgment of no infringement in Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., No. 24-1641. The decision offers important guidance for patent holders and generic manufacturers on the role of industry standards in interpreting scientific terminology during claim construction, prosecution history estoppel, and the disclosure-dedication rule.
Client Alert | 4 min read | 05.05.26
Client Alert | 3 min read | 12.24.24
Only Drugs Allowed: Federal Circuit Affirms Order To Delist Device Patents From the Orange Book
Firm News | 4 min read | 08.15.24
Recognition
- Best Lawyers: Ones to Watch in America, Illinois Commercial Litigation, 2025–2026
- Illinois Institute of Technology: Biomedical Engineering Distinguished Undergraduate Alumnus, 2017
- Indiana University Maurer School of Law: Dean’s Honors, Fall 2011, Spring/Fall 2013
- Illinois Institute of Technology: Camras Scholarship, Dean’s List, and Tau Beta Pi, 2007–2011
Joshua 's Insights
Client Alert | 3 min read | 05.26.26
On May 13, 2026, the U.S. Court of Appeals for the Federal Circuit affirmed a district court judgment of no infringement in Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., No. 24-1641. The decision offers important guidance for patent holders and generic manufacturers on the role of industry standards in interpreting scientific terminology during claim construction, prosecution history estoppel, and the disclosure-dedication rule.
Client Alert | 4 min read | 05.05.26
Client Alert | 3 min read | 12.24.24
Only Drugs Allowed: Federal Circuit Affirms Order To Delist Device Patents From the Orange Book
Firm News | 4 min read | 08.15.24
Insights
Federal Circuit Denies En Banc Rehearing for Hepatitis Drug Patent Ruling
|10.27.14
Joshua 's Insights
Client Alert | 3 min read | 05.26.26
On May 13, 2026, the U.S. Court of Appeals for the Federal Circuit affirmed a district court judgment of no infringement in Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., No. 24-1641. The decision offers important guidance for patent holders and generic manufacturers on the role of industry standards in interpreting scientific terminology during claim construction, prosecution history estoppel, and the disclosure-dedication rule.
Client Alert | 4 min read | 05.05.26
Client Alert | 3 min read | 12.24.24
Only Drugs Allowed: Federal Circuit Affirms Order To Delist Device Patents From the Orange Book
Firm News | 4 min read | 08.15.24
